Literature DB >> 24576029

Endometrial carcinoma in women aged 40 years and younger.

Karuna Garg1, Robert A Soslow.   

Abstract

CONTEXT: Endometrial carcinoma is a disease of older postmenopausal women, and is relatively uncommon in patients younger than 40 years. Endometrial carcinomas in this age group may be familial, associated with Lynch syndrome, or sporadic.
OBJECTIVES: To present our current knowledge of endometrial carcinomas in women younger than 40 years. DATA SOURCES: The review is based on previously published articles on this topic.
CONCLUSIONS: Most endometrial carcinomas that occur in this age group are associated with estrogen excess. They are usually low-grade endometrioid carcinomas that present at low stages and are associated with favorable clinical outcomes. Tumors associated with mismatch repair abnormalities and Lynch syndrome appear to be distinct, with worse prognostic factors and, possibly, clinical behavior. Conservative hormonal therapy and ovarian conservation are reasonable considerations in the management of these young patients, but carry the risk of tumor progression, recurrence, and an occult synchronous or metachronous ovarian carcinoma.

Entities:  

Mesh:

Year:  2014        PMID: 24576029     DOI: 10.5858/arpa.2012-0654-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  20 in total

1.  Proliferation and metastatic potential of endometrial cancer cells in response to metformin treatment in a high versus normal glucose environment.

Authors:  Amanda de Barros Machado; Vania Dos Reis; Sebastian Weber; Julia Jauckus; Ilma Simoni Brum; Helena von Eye Corleta; Thomas Strowitzki; Edison Capp; Ariane Germeyer
Journal:  Oncol Lett       Date:  2016-08-23       Impact factor: 2.967

Review 2.  Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.

Authors:  Ting-Tai Yen; Tian-Li Wang; Amanda N Fader; Ie-Ming Shih; Stéphanie Gaillard
Journal:  Int J Gynecol Pathol       Date:  2020-01       Impact factor: 3.326

Review 3.  Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?

Authors:  Adele Wong; Joanne Ngeow
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

4.  Understanding Molecular Landscape of Endometrial Cancer through Next Generation Sequencing: What We Have Learned so Far?

Authors:  Siti-Syazani Suhaimi; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2016-11-01       Impact factor: 5.810

Review 5.  Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer.

Authors:  Peng Jia; Yan Zhang
Journal:  Oncotarget       Date:  2017-06-07

6.  Changes of The Uterine Tissue in Rats with Polycystic Ovary Syndrome Induced by Estradiol Valerate.

Authors:  Ghadire Mirabolghasemi; Zahra Kamyab
Journal:  Int J Fertil Steril       Date:  2016-11-11

Review 7.  Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.

Authors:  Ruijin Shao; Xin Li; Yi Feng; Jin-Fang Lin; Håkan Billig
Journal:  J Exp Clin Cancer Res       Date:  2014-05-11

8.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Authors:  Nicoletta Colombo; Carien Creutzberg; Frederic Amant; Tjalling Bosse; Antonio González-Martín; Jonathan Ledermann; Christian Marth; Remi Nout; Denis Querleu; Mansoor Raza Mirza; Cristiana Sessa
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

9.  Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.

Authors:  Alli Straubhar; Andrew P Soisson; Mark Dodson; Elise Simons
Journal:  Gynecol Oncol Rep       Date:  2017-05-10

10.  The MCM3AP-AS1/miR-126/VEGF axis regulates cancer cell invasion and migration in endometrioid carcinoma.

Authors:  Jie Yu; Qiqi Fan; Lingling Li
Journal:  World J Surg Oncol       Date:  2021-07-13       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.